JP2002508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508338A5
JP2002508338A5 JP2000538720A JP2000538720A JP2002508338A5 JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5 JP 2000538720 A JP2000538720 A JP 2000538720A JP 2000538720 A JP2000538720 A JP 2000538720A JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
composition according
lentivirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000538720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/025720 external-priority patent/WO1999030742A1/en
Publication of JP2002508338A publication Critical patent/JP2002508338A/ja
Publication of JP2002508338A5 publication Critical patent/JP2002508338A5/ja
Pending legal-status Critical Current

Links

JP2000538720A 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用 Pending JP2002508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2002508338A JP2002508338A (ja) 2002-03-19
JP2002508338A5 true JP2002508338A5 (enExample) 2006-01-26

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538720A Pending JP2002508338A (ja) 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用

Country Status (6)

Country Link
EP (1) EP1037669A4 (enExample)
JP (1) JP2002508338A (enExample)
KR (1) KR20010033062A (enExample)
AU (1) AU749059B2 (enExample)
CA (1) CA2314683A1 (enExample)
WO (1) WO1999030742A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
DK1616012T3 (da) 2003-04-24 2008-04-21 San Raffaele Centro Fond Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf
ES2662030T3 (es) 2007-10-15 2018-04-05 Admedus Vaccines Pty Limited Sistema de construcciones y usos para el mismo
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028565A1 (en) * 1995-03-16 1996-09-19 Hisamitsu Pharmaceutical Co., Inc. Novel gene recombinant
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1123497A (en) * 1995-11-28 1997-06-19 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
CN100390291C (zh) * 1995-11-28 2008-05-28 约翰斯·霍普金斯大学医学院 条件复制型病毒载体及其用法
NZ331369A (en) * 1996-02-21 2001-04-27 Franco Lori Use of a genetic construct that directs virus expression in a lymphoid organ or a transduced cell thereof for genetic immunization
JP2000506727A (ja) * 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
AU734968B2 (en) * 1996-07-22 2001-06-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vectors for inhibiting HIV and tumor growth
AU7332198A (en) * 1997-03-06 1998-09-22 Klaus Uberla Lentivirus based vector and vector system
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors

Similar Documents

Publication Publication Date Title
CA2022539A1 (en) Albumin derivatives with therapeutic functions
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
AU2002317841A1 (en) Use of fkbp chaperones as expression tool
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
JP2002508338A5 (enExample)
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
AU3485800A (en) Inhibitors of aspartyl protease
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
WO2000061067A3 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
NO940810L (no) Behandling av virusinfeksjoner
CA2195125A1 (en) Difluorostatone antiviral agents
BG101175A (bg) Тройна анти-нiv комбинация
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
FR2647809B1 (fr) Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
WO1999061011A3 (de) Verwendung eines arzneimittels mit einem gehalt an tyrothricin zur behandlung von virusinfektionen
RU2003116404A (ru) Штамм вируса западного энцефаломиелита лошадей (western encephalomyelitis virus-wee 163-a) гкв n 964 для приготовления диагностических и профилактических препаратов
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
Dawson Origin of AIDS discovered